Trials / Active Not Recruiting
Active Not RecruitingNCT04458272
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DS-1001b | 250 mg, twice daily, continuous oral administration |
Timeline
- Start date
- 2020-07-08
- Primary completion
- 2023-03-10
- Completion
- 2026-08-31
- First posted
- 2020-07-07
- Last updated
- 2026-03-20
Locations
11 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04458272. Inclusion in this directory is not an endorsement.